- blocking peptide
- coli recombinant
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
- The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs.
- What Drives Innovation: The Canadian Touch on Liposomal Therapeutics.
DM us for scientific support 8AM - 1AM UTC Mon - Fri. Serving life science researchers globally to achieve their mission, faster.
Webinar alert. Interested in actin and cell fusion? Don’t miss Prof. Sophie Martin’s talk at the digital “#CellCycle Conference” on Wednesday, Oct 5. Register now ⬇️⬇️
@SophieMartinLab @unil @DeRobertus @Thorpelab
What does the future hold for the AML research community? To mark the end of this year’s #BloodCancerAwarenessMonth, we asked @PaoloGallipoli from @QMBCI to share his thoughts. Find out more and get insights on the epigenetic landscape of #AML, here: https://go.myabcam.com/epigenetic-landscape-of-aml
Today on #WorldAlzheimersDay, we’re acknowledging the continuous and collaborative effort from the research community and celebrating recent progress. Find out more and hear how biomarkers are offering a promising avenue from @sudha_md, here: https://go.myabcam.com/world_alzheimers_day_2022 @UTHealthSA
Diverse teams produce more novel and influential ideas - a tremendous piece of work from @UzziLeadership and team who analyzed +6M papers in 45 different areas of medicine – read more: https://www.pnas.org/doi/full/10.1073/pnas.2200841119#executive-summary-abstract
#diversitymatters @Tanyaty8 @bfjo @KelloggSchool @NICOatNU @PNASNews
A warm welcome from the Abcam community, @luba_greenwood. We are excited to have you join us in our journey to advance scientific breakthroughs.